Endocrine therapy is generally recommended for patients with HR+/HER2-metastatic breast cancer, with the exception of those ...

NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R ...

In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.

Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot ...

Background Pulsed field ablation (PFA) has emerged as a promising non-thermal alternative to conventional atrial fibrillation ...

Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with ...